AUR-1001 is a first in class pathogenic-tailored drug for the prevention of thrombosis and fetal loss in patients with anti-phospholipid syndrome. There is an unmet medical need for new treatment in this condition (increasing awareness of APS link)
The proposed drug is a human monoclonal antibody AUR-1001 directed against beta-2GPI. AUR-1001 competes with the patients “pathogenetic” autoantibodies that trigger the thrombotic events starting the complement cascade. AUR-1001 has higher affinity than patient autoantibodies, displaces them from the target and prevents the complement activation and the thrombogenic response.
The invention of AUR-1001 and its efficacy in animal models of human APS is described in a paper published in Blood. AUR-1001 human monoclonal antibody and its activity are covered in a patent application with a 2013 priority date.
The antiphospolipid syndrome (APS) is a medical condition that can cause blood clots to form within the arteries or vein. Depending on the location, extension and tissue damage of the thrombus formation, APS can give origin to a variety of clinical conditions that can be grouped as follows
AUR-1001 was engineered by world experts of APS. Its activity on prevention of thrombus formation and clinical manifestations of APS has been demonstrated in animals and results published in international peer reviewed journal (link)